<DOC>
	<DOCNO>NCT00006100</DOCNO>
	<brief_summary>RATIONALE : Biological therapy use different way stimulate immune system stop cancer cell grow . Donor white blood cell treat laboratory Epstein-Barr virus may effective treatment Hodgkin 's lymphoma . PURPOSE : Phase I trial study effectiveness allogeneic Epstein-Barr virus-specific cytotoxic T cell treat patient progressive , relapse , refractory Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes Treating Patients With Progressive , Relapsed , Refractory Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity allogeneic Epstein Barr virus ( EBV ) -specific cytotoxic T-lymphocytes ( EBV CTL ) patient progressive , relapse , refractory EBV-positive Hodgkin 's lymphoma . - Detect alteration anti-EBV cellular immunity patient treat EBV CTL . OUTLINE : Donors undergo leukapheresis . Epstein Barr virus-specific cytotoxic T lymphocytes ( EBV CTL ) culture vitro . Patients receive infusion EBV CTL 10 minute day 0 . The EBV CTL infusion precede 3 dos fludarabine . Patients receive interleukin-2 injection 12 day EBV CTL infusion . Patients follow weekly 1.5 month , twice month 1.5 month , monthly 3 month . PROJECTED ACCRUAL : A total 9 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove Hodgkin 's lymphoma Progressive , relapse , refractory disease prior chemotherapy , radiotherapy , and/or stem cell transplantation Epstein Barr virus ( EBV ) positive immunohistochemical stain LMP1 2 OR presence EBV RNA ( EBER ) Availability HLA identical haploidentical donor cytotoxic Tlymphocytes , meet follow criterion : EBV seropositive HIV negative HTLV1 negative Hepatitis B surface antigen hepatitis B core antibody IgM negative Hepatitis C antibody negative Must share least 1 HLA haplotype donor PATIENT CHARACTERISTICS : Age : 18 75 Performance status : Not specify Life expectancy : At least 8 week Hematopoietic : Not specify Hepatic : Bilirubin le 2.0 mg/dL SGOT/SGPT le 2.5 time normal ( unless liver metastasis present ) If liver involvement disease , obvious relationship SGOT/SGPT disease activity require No hepatic dysfunction cause moribundity Renal : Creatinine clearance great 50 mL/min No renal dysfunction cause moribundity Cardiovascular : No cardiac dysfunction cause moribundity Pulmonary : No pulmonary dysfunction cause moribundity Other : No neurologic dysfunction cause moribundity No history severe transfusion reaction blood product ( include fetal calf serum ) Not pregnant PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics No concurrent antimetabolites Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2005</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
</DOC>